69 related articles for article (PubMed ID: 21206970)
1. PPARγ is functionally expressed in clear cell renal cell carcinoma.
Collet N; Théoleyre S; Rageul J; Mottier S; Jouan F; Rioux-Leclercq N; Fergelot P; Patard JJ; Masson D; Denis MG
Int J Oncol; 2011 Mar; 38(3):851-7. PubMed ID: 21206970
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor gamma is frequently underexpressed in renal cell carcinoma.
Yuan J; Takahashi A; Masumori N; Itoh N; Tsukamoto T
Int J Urol; 2006 Mar; 13(3):265-70. PubMed ID: 16643621
[TBL] [Abstract][Full Text] [Related]
3. HtrA3 is regulated by 15-deoxy-Delta12,14-prostaglandin J2 independently of PPARgamma in clear cell renal cell carcinomas.
Théoleyre S; Mottier S; Masson D; Denis MG
Biochem Biophys Res Commun; 2010 Apr; 394(3):453-8. PubMed ID: 19951697
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
5. Altered expression of beta-catenin in renal cell cancer and transitional cell cancer with the absence of beta-catenin gene mutations.
Bilim V; Kawasaki T; Katagiri A; Wakatsuki S; Takahashi K; Tomita Y
Clin Cancer Res; 2000 Feb; 6(2):460-6. PubMed ID: 10690524
[TBL] [Abstract][Full Text] [Related]
6. Low expression of ORF4, a dominant negative variant of peroxisome proliferator-activated receptor gamma, in colorectal adenocarcinoma.
Bouancheau D; Jarry A; Mottier S; Toquet C; Masson D; Mosnier JF; Laboisse CL; Denis MG
Oncol Rep; 2007 Aug; 18(2):489-95. PubMed ID: 17611675
[TBL] [Abstract][Full Text] [Related]
7. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness.
Kosari F; Parker AS; Kube DM; Lohse CM; Leibovich BC; Blute ML; Cheville JC; Vasmatzis G
Clin Cancer Res; 2005 Jul; 11(14):5128-39. PubMed ID: 16033827
[TBL] [Abstract][Full Text] [Related]
8. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney.
Aydin H; Chen L; Cheng L; Vaziri S; He H; Ganapathi R; Delahunt B; Magi-Galluzzi C; Zhou M
Am J Surg Pathol; 2010 Nov; 34(11):1608-21. PubMed ID: 20924276
[TBL] [Abstract][Full Text] [Related]
9. Loss of expression of TIMP3 in clear cell renal cell carcinoma.
Masson D; Rioux-Leclercq N; Fergelot P; Jouan F; Mottier S; Théoleyre S; Bach-Ngohou K; Patard JJ; Denis MG
Eur J Cancer; 2010 May; 46(8):1430-7. PubMed ID: 20194016
[TBL] [Abstract][Full Text] [Related]
10. Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma.
Wondergem B; Zhang Z; Huang D; Ong CK; Koeman J; Hof DV; Petillo D; Ooi A; Anema J; Lane B; Kahnoski RJ; Furge KA; Teh BT
Cancer Res; 2012 Sep; 72(17):4361-71. PubMed ID: 22805307
[TBL] [Abstract][Full Text] [Related]
11. The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas.
Allory Y; Matsuoka Y; Bazille C; Christensen EI; Ronco P; Debiec H
Clin Cancer Res; 2005 Feb; 11(3):1190-7. PubMed ID: 15709188
[TBL] [Abstract][Full Text] [Related]
12. Genetic analysis of peroxisome proliferator-activated receptor gamma1 splice variants in human colorectal cell lines.
Fiatte C; Huin C; Bertin I; Lesuffleur T; Pluvinet A; Touche N; Plénat F; Dauça M; Domenjoud L; Schohn H
Int J Oncol; 2006 Dec; 29(6):1601-10. PubMed ID: 17089002
[TBL] [Abstract][Full Text] [Related]
13. MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells.
Tang SW; Chang WH; Su YC; Chen YC; Lai YH; Wu PT; Hsu CI; Lin WC; Lai MK; Lin JY
Cancer Lett; 2009 Jan; 273(1):35-43. PubMed ID: 18809243
[TBL] [Abstract][Full Text] [Related]
14. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
15. D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta.
Li X; Tan X; Yu Y; Chen H; Chang W; Hou J; Xu D; Ma L; Cao G
Cancer; 2011 Sep; 117(18):4201-11. PubMed ID: 21387281
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas.
Jones TD; Eble JN; Wang M; MacLennan GT; Delahunt B; Brunelli M; Martignoni G; Lopez-Beltran A; Bonsib SM; Ulbright TM; Zhang S; Nigro K; Cheng L
Clin Cancer Res; 2005 Oct; 11(20):7226-33. PubMed ID: 16243792
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions.
Suzuki T; Hayashi S; Miki Y; Nakamura Y; Moriya T; Sugawara A; Ishida T; Ohuchi N; Sasano H
Endocr Relat Cancer; 2006 Mar; 13(1):233-50. PubMed ID: 16601291
[TBL] [Abstract][Full Text] [Related]
18. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
[TBL] [Abstract][Full Text] [Related]
19. Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma.
Morikawa T; Sugiyama A; Kume H; Ota S; Kashima T; Tomita K; Kitamura T; Kodama T; Fukayama M; Aburatani H
Clin Cancer Res; 2007 Oct; 13(19):5703-9. PubMed ID: 17908959
[TBL] [Abstract][Full Text] [Related]
20. PPARγ is dispensable for clear cell renal cell carcinoma progression.
Sanchez DJ; Steger DJ; Skuli N; Bansal A; Simon MC
Mol Metab; 2018 Aug; 14():139-149. PubMed ID: 29866440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
